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Abstract
Introduction When reporting adverse drug reactions to pharmacovigilance centres, patients and consumers can describe 
adverse drug reactions experienced in free-text format. Recently, a patient-friendly adverse drug reaction terms list was 
introduced in the adverse drug reaction report form in the UK to facilitate this reporting.
Objective The objective of this study was to evaluate the actual use of the patient-friendly terms list in the adverse drug 
reaction report form and its association with the type of adverse drug reactions reported.
Methods We conducted a database study in which we reviewed the list’s use for all reported adverse drug reactions by 
patients and consumers to the pharmacovigilance centre in the UK via the online report form between August and Septem-
ber 2017. Descriptive statistics were used. In addition, for adverse drug reactions reported more than 20 times, Chi-squared 
tests were used to test for differences in the number of reports in which the patient-friendly terms list was used and those in 
which the adverse drug reaction was entered as free text.
Results In total, 888 reports were received. In 185 reports (21%), the patient-friendly terms list was used to enter an adverse 
drug reaction. In total, the reports contained 3227 adverse drug reactions. Nausea, headache, diarrhoea, dizziness, insomnia, 
anxiety, depression, fatigue, tiredness, vomiting, appetite lost, joint pain, chest pain, constipation and pain were reported 
more than 20 times. Five of these adverse drug reactions (i.e. nausea, diarrhoea, dizziness, insomnia and constipation) were 
reported significantly more often in reports where the adverse drug reactions were selected from the patient-friendly terms 
list.
Conclusions Most people chose to describe adverse drug reactions in their own words rather than selecting adverse drug 
reactions from a patient-friendly terms list. Although the patient-friendly terms list may be a useful feature for some patients 
or for some adverse drug reactions, it should not replace the option for patients to describe adverse drug reactions in their 
own words.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 4-019-00800 -x) contains 
supplementary material, which is available to authorized users.
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Key Points 
People reporting adverse drug reactions to a pharma-
covigilance centre more often describe their experiences 
using free text rather than by selecting a term from a list.
The use of a patient-friendly terms list may depend on 
the type of adverse drug reaction reported.
The patient-friendly terms list may support some report-
ers but should not replace the possibility for people to 
describe an adverse drug reaction in their own words.
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1 Introduction
Post-marketing surveillance is crucial for monitoring a 
drug’s safety profile after its market approval. In the past, 
reporting of adverse drug reactions (ADRs) to the national 
agency could only be completed by healthcare profession-
als. Over time, the interest in reports submitted by patients 
or consumers has increased, as they are seen as an impor-
tant source of information about ADRs [1–3]. Currently, 
many pharmacovigilance centres worldwide allow both 
patients and consumers and healthcare professionals to 
report ADRs directly to the national agency [4].
There are differences across pharmacovigilance centres 
in the ADR reporting process, for instance, in the man-
ner in which people can report ADRs (e.g. via telephone, 
paper forms, web-based forms, mobile application), the 
criteria within the report form and how the reporter can 
answer the questions in the report form (e.g. free text, 
radio button, drop-down lists) [5–7]. In most report forms, 
individuals can describe the ADR experienced as free text. 
In the online report form of the Medicines and Healthcare 
products Regulatory Agency (MHRA) in the UK (i.e. the 
Yellow Card scheme) [8], individuals can also select ADR 
terms from a list that appears after a few letters are entered 
in addition to having a free-text field to describe their 
experience. The list is made up of terms from the Medical 
Dictionary for Regulatory Activities (MedDRA®) [9]—a 
standardised international terminology—and selected 
terms can be directly transferred into the MHRA database 
without the need for manual coding from free text.
The use of a list to select ADRs in an online report form 
could thus reduce the time needed for assessors to code 
reported ADRs and could ease the process of reporting 
an ADR. However, in a small pilot study that we con-
ducted, patients indicated they preferred to describe an 
ADR experienced in their own words rather than selecting 
a term from a list. Reasons for this preference were that 
they thought more accurate information could be provided 
using their own words when using free text and that they 
were concerned with the difficulty of understanding medi-
cal terms used in such a list [see Electronic Supplementary 
Material 1]. The latter might be resolved by using a list 
with patient-friendly terms. Such patient-friendly terms 
have been proposed for reporting tools used by patients 
[10]. Additionally, a qualitative study showed that the use 
of patient-friendly terms is an important factor for using 
a mobile application for ADR reporting [11]. However, 
for some ADRs, patients may still prefer to use their own 
words.
Recently, a “patient-friendly list” of MedDRA® was 
developed in English by the MedDRA® Maintenance and 
Support Services Organization and other partners of the 
Web-Recognising Adverse Drug Reactions (WEB-RADR) 
project [12]. This list includes patient-friendly terms for 
approximately 1400 of the lowest level terms (LLTs) from 
MedDRA® and is available online [13]. It contains ADR 
terms, using patients’ and consumers’ own texts, of the 
most frequently reported ADRs by individuals to phar-
macovigilance centres. The patient-friendly terms list 
thus generally reflects the language used by individuals 
submitting ADR reports but is not (yet) comprehensive. 
Some of the terms on the list are of a technical or medical 
nature and might not represent the typical language some 
individuals would use to report that ADR. It is possible 
that, whilst the ADR was originally reported by a patient, 
another individual may have assisted and translated the 
ADR into more medical language for the purpose of sub-
mitting the report. Therefore, some terms on the list may 
still be difficult for people to understand (see the ESM 1).
In this study, we aimed to evaluate the usefulness of the 
currently available patient-friendly terms list for reporting 
ADRs by patients and consumers. More specifically, our 
aims were to evaluate the actual use of the patient-friendly 
terms list and its association with the type of ADRs reported.
2  Methods
We conducted a database study in the context of the WEB-
RADR project. Data of ADRs spontaneously reported by 
patients and consumers through the MHRA’s Yellow Card 
scheme online form were used.
2.1  Procedure and Included Reports
The patient-friendly terms list developed by the MedDRA® 
Maintenance and Support Services Organization and other 
partners of the WEB-RADR project was incorporated in the 
patient and consumer version of the Yellow Card scheme 
online form (https ://yello wcard .mhra.gov.uk/) on 2 August, 
2017. The patient-friendly terms appear when a person 
enters a few letters in the text field to describe the ADR. The 
ADR terms that appear contain the exact entered letters; they 
do not include other medically related MedDRA® terms that 
do not contain the entered letters. For an example, see the 
ESM 2. ADRs selected from the patient-friendly terms list 
were recorded as MedDRA® LLTs in the database, whereas 
ADRs entered as free text were linked to MedDRA® LLTs 
by trained pharmacovigilance assessors.
The data for this study were extracted on 18 September, 
2017. All reports received in this time period from patients 
and consumers were included. We assessed how many peo-
ple selected an ADR from the list or entered the ADR as free 
text, and which MedDRA® terms were documented via both 
methods of ADR reporting. Use of the patient-friendly terms 
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list was assumed when there was an exact match between 
the reported ADR and a term from the list, considering that 
the drop-down list appears when typing the first letters of a 
term on the list.
2.2  Analyses
Descriptive statistics were used to describe the number 
of received reports per reporting method, the number of 
ADRs at the LLT level, and the sex and age of the patients 
for which an ADR was reported. The association between 
the reporting methods and the type of reported ADRs was 
assessed for the ADRs of which more than 20 reports were 
received. Chi-squared tests or Fisher’s exact tests in the case 
of cells with fewer than five cases were used to test for dif-
ferences between the reporting methods in the number of 
reports received for these ADRs. P-values < 0.05 were con-
sidered statistically significant. The analyses were conducted 
using Stata Version 14.2 (Stata Corp., College Station, TX, 
USA).
3  Results
There were 888 ADR reports received in the study period. In 
69% of the reports, a female patient was involved. The age 
ranged from 1 to 94 years (mean: 45, standard deviation: 20). 
In 185 reports (21%), the patient-friendly terms list was used 
to enter the ADR(s). In 137 reports (15%), some ADRs were 
reported as free text while other ADRs were selected from 
the patient-friendly terms list. Reports in which the list was 
used concerned younger patients than the reports in which 
the ADRs were entered as free text (on average 37 years vs. 
49 years; Table 1).
In total, the reports contained 3227 ADRs of which 
nausea, headache, diarrhoea, dizziness, insomnia, anxiety, 
depression, fatigue, tiredness, vomiting, appetite lost, joint 
pain, chest pain, constipation and pain were reported more 
than 20 times. Five of these ADRs (i.e. nausea, diarrhoea, 
dizziness, insomnia and constipation) were more often 
mentioned in reports where the ADR was selected from the 
patient-friendly terms list (Table 2). Pain was more often 
mentioned using free text (21 reports vs. 0 reports; p = 
0.017). Depression was also only mentioned in reports using 
free text. However, this term was not included in the patient-
friendly terms list. An overview of all reported ADRs at the 
LLT level is presented online (see the ESM 3).
4  Discussion
Our study shows that for the majority of the reports to a 
pharmacovigilance centre, people chose to describe the 
ADRs in their own words rather than selecting ADRs from 
a patient-friendly terms list. Still, one fifth of the people 
used the patient-friendly terms list when reporting an 
ADR. These patients were on average more than 10 years 
younger. It seems that the use of the patient-friendly terms 
list depends on the ADR it concerns.
Our results indicate that from a patient perspective, the 
free-text option to describe an ADR should be available and 
should not be replaced by a list for selecting ADRs. Free 
text provides individuals the option to use their own words. 
Previously, it has been shown that patients provide richer 
and more detailed information about ADRs in a report than 
healthcare professionals [14]. This suggests that informa-
tion could be lost when people cannot describe the ADRs 
they experienced in their own words. A recent study also 
showed that this additional information provided by patients 
is important in the identification and assessment of safety 
signals [15]. The MHRA currently allows a hybrid approach 
where terms are presented in a drop-down list, but do not 
necessarily have to be selected. Additionally, there is a large 
free-text field, which allows for unstructured data and differ-
ent patient preferences.
The use of a patient-friendly terms list in the ADR report 
form may have advantages for the handling of the reports. 
For instance, it is expected to save time when assessors 
do not need to code a description of an ADR as entered 
by patients and consumers to the terms provided in Med-
DRA®. However, guidelines about MedDRA® coding 
already mention the challenge of selecting the right term for 
Table 1  Characteristics of the adverse drug reaction (ADR) reports
SD standard deviation
a Sex was unknown in 4 reports
b Age was missing in 64 reports
Overall Reports in which ADRs were 
entered as free text
Reports in which ADRs were selected 
from the patient-friendly terms list
Use of both options
Number of reports (%) 888 566 (64) 185 (21) 137 (15)
Female sex (%)a 613 (69) 372 (66) 140 (76) 101 (74)
Age, mean (SD)b 45 (20) 49 (20) 37 (16) 40 (18)
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professionals, where for instance a difference of one letter 
can impact the meaning of a symptom [16]. It is question-
able whether patients and consumers will be able to make 
such distinctions when selecting terms from a predefined 
list. It is therefore important that the terms in the list are 
clear and unambiguous. Further studies are needed to assess 
the validity of reports in which ADRs are selected from a 
patient-friendly terms list. In particular, it should be assessed 
whether the terms sufficiently and correctly reflect what the 
patients experienced.
Our study showed that the type of ADR may influence 
the use of the patient-friendly terms list. It could be that 
for some ADRs the term is so unambiguous that more peo-
ple are content to select it from a list, as we observed for 
nausea, diarrhoea, dizziness, insomnia and constipation. 
Moreover, a less specific ADR, i.e. pain, was shown to be 
more often reported using free text. However, other ADRs 
that seem unambiguous, such as headache or fatigue, were 
not more often selected from the list. More in-depth studies 
are needed to understand when individuals prefer to describe 
ADRs in their own words. Furthermore, we observed that 
reports of ADRs using the patient-friendly terms list con-
cerned patients that were generally younger than when free 
text was used. We do not know whether older people had 
difficulties with the terms in the list or had a preference for 
entering the ADR as free text. A previous study showed 
that older people may have more trouble with drop-down 
lists [17]. Furthermore, older people may also experience 
different types of ADRs [18], which may be more difficult 
to select from a list. Although the person for whom an ADR 
is reported is not necessarily the same person as the indi-
vidual sending the report (e.g. a daughter/son reporting an 
ADR for an elderly parent), our results suggest that more 
research is needed to assess the association between patient 
characteristics and the preference or ability to select ADRs 
from a patient-friendly terms list.
For more widespread use in regulatory and industry 
online ADR reporting portals, the patient-friendly terms 
list will need to evolve with the deletion of terms that are 
difficult to understand and the addition of terms that are 
more appropriate for use by patients and consumers. To date, 
the list has only been developed in English; however, Med-
DRA® is available in ten other languages, including French, 
Spanish, Dutch, Japanese and Chinese. The original list was 
derived from actual patient reports in English. Therefore, 
for other languages, data sources of patient-reported terms 
are needed to develop appropriate lists specific to those lan-
guages. It may not be appropriate to take the English list 
and convert it into other languages because a term that is 
a frequently reported and well-understood term in English 
may not necessarily be a “patient-friendly” or common col-
loquial expression in another language.
Table 2  Characteristics of the 
adverse drug reactions (ADRs) 
entered as free text and selected 
from the patient-friendly terms 
list
LLT lowest level term
a Measured using Chi-squared tests
b This ADR was not on the patient-friendly terms list
c Measured using the Fisher’s exact test
Overall Reports in which ADRs 
were entered as free text
Reports in which ADRs were 
selected from the patient-friendly 
terms list
P  valuea
Number of ADRs 
at the LLT level
3227 2545 682
Overall, 10 most commonly reported ADRs (% of number of ADRs at the LLT level)
 Nausea 78 (2.4) 54 (2.1) 24 (3.5) 0.035
 Headache 77 (2.4) 65 (2.6) 12 (1.8) 0.227
 Diarrhoea 62 (1.9) 36 (1.4) 26 (3.8) < 0.001
 Dizziness 54 (1.7) 36 (1.4) 18 (2.6) 0.027
 Insomnia 33 (1.0) 20 (0.8) 13 (1.9) 0.010
 Anxiety 29 (0.9) 21 (0.8) 8 (1.2) 0.393
 Depression 28 (0.9) 28 (1.1) 0 (0.0)b 0.002c
 Fatigue 28 (0.9) 23 (0.9) 5 (0.7) 0.670
 Tiredness 28 (0.9) 22 (0.9) 6 (0.9) 0.969
 Vomiting 28 (0.9) 19 (0.8) 9 (1.3) 0.152
 Appetite lost 26 (0.8) 21 (0.8) 5 (0.7) 0.811
 Joint pain 24 (0.7) 18 (0.7) 6 (0.9) 0.641
 Chest pain 23 (0.7) 18 (0.7) 5 (0.7) 0.943
 Constipation 21 (0.7) 11 (0.4) 10 (1.5) 0.003
 Pain 21 (0.7) 21 (0.8) 0 (0) 0.013c
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4.1  Strengths and Limitations
This study is the first in which the use of the patient-friendly 
terms list of MedDRA® in an ADR report form was eval-
uated. A limitation is that we assumed an exact match 
between the reported ADR and the ADR on the patient-
friendly terms list as an indication of actual use of the list, 
while a person could still have fully typed the ADR that 
popped up from the list. Another limitation is that the list 
does not yet cover all ADRs and that there may not be a term 
best suited to describe the ADR. Finally, the duration of data 
collection, i.e. 1.5 months, may seem limited. However, 888 
reports were received in this period, which is in our opinion 
sufficient for an explorative assessment of the use of the 
patient-friendly terms list.
5  Conclusion
This study shows that most individuals choose to describe 
the ADRs in their own words rather than selecting ADRs 
from a patient-friendly terms list when they report ADRs to 
a pharmacovigilance centre. Therefore, the patient-friendly 
terms list may be a useful feature for some patients or for 
some ADRs but it should not replace the option for individu-
als to describe an ADR in their own words. Future studies 
are needed to understand which people and which ADRs 
the patient-friendly terms list may be a useful feature for an 
ADR report form.
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